The U.S. Food and Drug Administration announced plans to hire more than 1,000 new staffers and launched a pilot program allowing sponsors to email quick clarifications to the Office of New Drugs with three‑business‑day turnaround. FDA Commissioner Marty Makary described the initiative as a way to reduce development delays by giving sponsors faster feedback on meeting minutes and regulatory questions. The hiring push follows workforce reductions earlier in the year and missed review deadlines; the agency said the new positions cover reviewers, inspectors and mission‑critical roles. Biotech executives have pushed for regulatory stability, and sponsors will watch whether the program reduces uncertainty in trial design and NDA interactions or whether structural workforce gaps continue to hamper timely reviews.